STAT3 and familial pancreatic carcinoma: These novel STAT3 inhibitors show significant inhibition of STAT3 activation, STAT3 reporter promoter activity, and the growth of breast and pancreatic cancer cell lines in vitro and xenograft breast tumors derived from TNBC MDA-MB-231 cells, via oral administration [54].